Christos Fountzilas

Mar 28, 2024 | mdpi.com | Faithlore Gardner |Zev A. Wainberg |Christos Fountzilas |Nathan Bahary

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Mar 16, 2023 | onclive.com | Christos Fountzilas

Christos Fountzilas, MD, FACP, associate professor, oncology, Department of Medicine, co-leader, Gastrointestinal Clinical Disease Team, associate director for solid tumors, Early Phase Clinical Trials Program, Roswell Park Comprehensive Cancer Center, discusses findings from a study of molecular characterization in patients with colorectal cancer (CRC) treated with cetuximab (Erbitux), an EGFR inhibitor, and pembrolizumab (Keytruda), a PD-1 inhibitor.